Adding a new drug, ibrutinib, to usual treatment for brain lymphoma
Original title: Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid-stage test in people, so it is not yet care you can get from your own doctor.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests if adding a new drug to usual treatment helps people with a type of brain lymphoma.
Who this trial is for. This trial is for people just found to have primary central nervous system lymphoma who cannot get a transplant. It tests adding a drug called ibrutinib to the usual treatment.
Where it stands. The trial wants to learn if the added drug lowers the chance of the lymphoma growing or spreading. It will also look at whether this is better or worse than usual care. The trial has not reported results yet.
What this means, and what it doesn't
What it could mean: This trial could help doctors learn if one more drug makes treatment work better. If you or someone you care for has this type of lymphoma, you could ask your care team about it. Whether someone can join is up to the trial team.
What it doesn't mean: A trial is a test, not a proven treatment. No one knows yet if adding this drug helps, and it could turn out to be worse. Being in a trial does not promise you will benefit. This is not a cure.
Source: ClinicalTrials.gov, September 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.